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Abstract
The possibility of reprogramming human somatic cells to pluripotency has opened unprecedented opportunities for creating 
genuinely human experimental models of disease. Inborn errors of metabolism (IEMs) constitute a greatly heterogeneous 
class of diseases that appear, in principle, especially suited to be modeled by iPSC-based technology. Indeed, dozens of IEMs 
have already been modeled to some extent using patient-specific iPSCs. Here, we review the advantages and disadvantages 
of iPSC-based disease modeling in the context of IEMs, as well as particular challenges associated to this approach, together 
with solutions researchers have proposed to tackle them. We have structured this review around six lessons that we have 
learnt from those previous modeling efforts, and that we believe should be carefully considered by researchers wishing to 
embark in future iPSC-based models of IEMs.
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CRISPR  Clustered regularly interspaced short palindro-
mic repeats
dAMP   Deoxyadenosine monophosphate
dGMP   Deoxyguanosine monophosphate
DGUOK  Deoxyguanosine kinase
ESCs   Embryonic stem cells




HipSci   Human Induced Pluripotent Stem Cells 
Initiative
IEMs  Inborn errors of metabolism
iPSCs   Induced pluripotent stem cells
LDL-C  Low-density lipoprotein-cholesterol
LSDs  Lysosomal storage disorders
MELAS   Mitochondrial encephalomyopathy, lactic 
acidosis and stroke episodes
MPSIIIB   Mucopolysaccharidosis type IIIB
NPC   Niemman-Pick disease type C
OAT  Ornithine-δ-aminotransferase
OMIM  Online mendelian inheritance in man
PD  Parkinson’s disease
SphK   Sphingosine kinase
SSIEM   Society for the Study of Inborn Errors of 
Metabolism
TALENs  Transcription activator-like effector nuclease
VEGF   Vascular endothelial growth factor
ZFN  Zinc-finger nucleases
1 Introduction
Inborn errors of metabolism (IEMs) are heritable monogenic 
disorders that often present congenitally with multi-system 
manifestations affecting various organs. Commonly, gene 
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mutations in IEMs lead to inadequate enzyme or transporter 
activity and result in the accumulation of toxic substrates or 
a deficiency of essential metabolites. Although individually 
rare, IEMs are collectively quite common, with an estimated 
incidence of 1 in 4000 newborns [1, 2]. Even though various 
therapeutic approaches, including replacement therapy and 
small molecule drugs, have proven effective to treat several 
IEMs, there is still no cure for most of them, emphasizing 
the critical need for developing disease-modifying strategies 
that can ameliorate or halt disease progression.
Gaining a better understanding of the pathophysiologi-
cal bases underlying IEMs is absolutely critical in order to 
develop new therapeutic agents. Animal models have pro-
vided invaluable insights into the pathophysiology of IEMs, 
but there remain questions of translatability to humans due 
to interspecies differences in physiology [3–6]. Additionally, 
recapitulating key phenotypes of IEMs in vivo has been chal-
lenging because transgenic animal models of these disorders 
are often nonviable or show early mortality [7]. Because of 
the limited availability of disease-relevant patients’ samples 
(especially for rare monogenic diseases with limited number 
of patients available worldwide and limited access to the 
affected tissues), there is an urgent need for the development 
of human cellular models that recapitulate the most salient 
features of IEMs in order to investigate disease progression 
and to develop new therapeutic approaches. In this sense, 
the advent of induced pluripotent stem cell (iPSC) technol-
ogy [8] has opened new perspectives for modeling human 
diseases. The possibility to reprogram human somatic cells 
to pluripotency offers an unprecedented opportunity to gen-
erate disease-specific iPSCs [9–12], for the development of 
cell-based experimental models.
In this review, we focus on the use of iPSC technology to 
model IEMs and how these models provide a valuable tool to 
set up innovative treatment approaches for particular IEMs. 
We discuss published iPSC models of inherited metabolic 
diseases and summarize the main lessons learnt from these 
efforts.
2  Induced pluripotent stem cells 
as a powerful tool for disease modeling
In 2006, Takahashi and Yamanaka published a major tech-
nological breakthrough in the field of disease modeling, 
describing a method for reprogramming terminally differen-
tiated adult dermal fibroblasts into cells with a gene expres-
sion profile and developmental potential similar to those of 
embryonic stem cells (ESCs) [8, 13, 14].
iPSC technology offers the possibility to generate 
patient-specific cells for modeling human diseases. While 
animal-based models have provided valuable insights into 
the pathogenic mechanisms of numerous human diseases 
[15–17], substantial species-specific differences prevent 
the recapitulation of key features characteristic of many 
human conditions [18–20]. Indeed, several rodent mod-
els have been described to not be adequate in the context 
of metabolic disorders: Lesch-Nyhan syndrome models 
do not recapitulate the common neurobehavioral aspects 
[21], vascular endothelial dysfunction is not recapitulated 
in Fabry disease models [22, 23], Niemman-Pick disease 
type C (NPC) models do not cover all aspects of the dis-
ease pathology [24], and the pathological phenotypes 
observed in sialidosis models appear to be shared across 
multiple lysosomal storage disorders (LSDs) and Alzhei-
mer’s disease [25]. Similarly, the use of primary cultures 
of patient-derived cells, while helpful for studying disease 
etiology, is limited by the lack of expandable sources of 
patients’ cells, particularly for hard-to-access cells such 
as neurons and cardiomyocytes. Therefore, iPSC-based 
disease modeling appears as an attractive alternative to 
animal- and primary cell-based methods.
Identification of novel therapeutic approaches requires 
recapitulating key features of IEMs and relevant patho-
genic mechanisms, a frequent limitation of conventional 
in vitro models. iPSC-based models can provide disease-
related phenotypes in cell types relevant for the specific 
disease, thus representing a clear advantage over the use of 
fibroblasts or immortalized cell lines. For example, hiPSC-
derived cells are more vulnerable to the toxic effects of 
substrate accumulation that are characteristic of several 
IEMs [26–28] and display a metabolic rate more simi-
lar to disease-relevant cells [29]. For inherited metabolic 
disorders affecting hepatocytes, immortalized cells lines 
are widely used. However, they do not resemble primary 
hepatocytes, have dysfunctional apoptotic pathways due to 
their carcinogenic nature and present restricted genotypic 
variability [30]. Similarly, primary hepatocytes, consid-
ered the gold standard for in vitro drug testing, gradually 
lose their hepatic functions during culture and are unable 
to proliferate [31]. Therefore, iPSC derivatives could 
provide an excellent alternative platform to overcome an 
important limitation associated with the identification of 
novel pharmacological treatments for IEMs.
Only fifteen years after the original description of 
induced reprogramming to pluripotency, enormous pro-
gress has been made in stem cell biology and regenerative 
medicine using iPSC technology [9, 24, 32–34]. Further-
more, iPSCs derived from healthy individuals and patients 
have accelerated advances in developing genuinely human 
experimental models of disease, novel pathogenic mecha-
nisms or associated phenotypes have been elucidated [25, 
26, 28, 35–37], new drugs initiated from iPSC-based 
screenings are in the pipeline [38–40] and the first clini-
cal trials using human iPSC-derived products have been 
initiated [24, 41–43].
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3  Modeling inborn errors of metabolism  
in vitro
IEMs are a class of heterogeneous and rare diseases 
commonly caused by a defect in metabolic proteins, usu-
ally an enzyme or a transporter, that result in accumula-
tion of harmful metabolites or deficiency of particular 
metabolites needed for cellular homeostasis [44]. Their 
classification can be difficult because of the multitude 
and variety of metabolic pathways involved. According 
to the hierarchical classification set forth by the Society 
for the Study of Inborn Errors of Metabolism (SSIEM), 
IEMs comprise 612 diseases with OMIM numbers, cat-
egorized into 15 main groups (www. ssiem. org/ resou rces/ 
resou rces/ inborn- errors- class ifica tion). Although disease 
modeling remains a challenge in the context of IEMs, 
to date, dozens of these disorders have been modeled to 
some extent using patient-specific iPSC. We have iden-
tified from scientific literature a total of 107 IEMs for 
which iPSC lines have been generated, referenced with a 
total of 291 publications (Supplemental Table 1), among 
which lysosomal disorders have attracted special atten-
tion (Fig. 1A). In combination with specific protocols for 
differentiating patient-specific iPSC into disease-relevant 
cell types, these models are able to recapitulate key phe-
notypic features of IEMs and provide insight into disease 
mechanisms, as well as aiding in the identification of 
novel drug targets (Fig. 1B). Some of the most successful 
efforts at IEM modeling, together with the main lessons 
learnt from them, are discussed below.
3.1  First lesson: iPSCs vs fibroblasts, highlighting 
the importance of the disease‑relevant cell 
type
For most IEMs, disease-relevant phenotypes cannot be 
investigated in fibroblasts, highlighting the importance of 
developing iPSC-derived models (Fig. 2). Nonetheless, in 
some cases, fibroblasts display disease-related phenotypes 
and thus, engaging into somatic cell reprogramming and 
subsequent iPSC differentiation might appear unnecessary. 
Several studies carried out with patients’ fibroblasts have 
contributed to our understanding of the pathogenic mecha-
nisms of diseases [45], and provided valuable readouts for 
screening novel compounds [46–48]. Using this approach, 
Lee et al. reported on the key role of vascular endothelial 
growth factor (VEGF) and sphingosine kinase (SphK) in 
NPC pathogenesis [45]. The activity of SphK, a crucial 
enzyme in modulating the levels of sphingosine, was sig-
nificantly decreased in fibroblasts from NPC patients, lead-
ing to abnormal sphingosine storage and autophagic defects. 
This dysfunction of SphK activity was linked to decreased 
VEGF expression. Thus, VEGF treatment ameliorated the 
NPC phenotype in patients’ fibroblasts and increased SphK 
activity. Several studies carried out with NPC fibroblasts, 
which showed an accumulation of unesterified cholesterol 
and lipids in lysosomal storage organelles, reported the 
evaluation of compound efficacy [46–48]. The benefit of 
compounds such as β-cyclodextrins, histone deacetylase 
inhibitors or rapamycin has been confirmed using NPC 
patient-derived fibroblasts. However, later studies found 
Fig. 1  Analysis of published studies using iPSC technology for 
modeling of IEMs A  Number of publications related to each 
of the fifteen main IEM groups as classified by the Society for 
the Study of Inborn Errors of Metabolism (SSIEM; classifica-
tion  available at www. ssiem. org/ images/ centr alsto re/ resou rces/ 
SSIEM Class ifica tionI EM2011. pdf). B  Distribution of the 291 
publications reviewed for the current study, indicating those that 
reported recapitulation of phenotypic features of IEMs, screen-
ing of novel compounds, and the combination of iPSC technology 
with gene editing techniques
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differences in drug responses between NPC neuronal cells 
and dermal fibroblasts even though they were derived from 
the same NPC patient. The application of human NPC neu-
ral stem cells as a cell-based disease model established that 
six out of the nine compounds reported as efficacious in 
NPC, fibroblasts, and mouse models, did not have significant 
effects in these cells [29]. Using the appropriate molecular 
and biochemical context is also fundamental for decipher-
ing new cell type-specific pathogenic mechanisms: Seol 
et al. provided the first evidence that lysosomal sialidase 
gene (NEU1) deficiency alters, not only lysosomal dynam-
ics, but also autophagic activity [25]; Odaka et al. revealed 
defective presynaptic exocytosis and excessive enhance-
ment of AMPA-evoked  Ca2+ influx in sialidosis [26]; and 
Liedtke et al. uncovered possible differences between NPC1 
and NPC2 that showed indistinguishable biochemical phe-
notypes [28], among others.
IEMs comprise metabolic defects that can either affect 
almost all tissues, such as disorders of glycosylation, or spe-
cific cell types in which the mutated enzyme plays a critical 
role. In this sense, patient’s fibroblast can provide valuable 
information for diseases in which the associated biochemi-
cal defects are ubiquitously altered in nearly all cell types or 
the underlying phenotypes of the disease can be observed 
systemically.
3.2  Second lesson: Important metabolic defects 
underlie IEMs ‑but iPSCs do not seem to care
For most IEMs modeled through iPSC-based technology to 
date, the metabolic defects that characterize these diseases 
do not seem to affect iPSC generation or maintenance, 
thereby enabling successful modeling of those diseases. 
Nevertheless, in some particular cases, iPSC generation 
from diseased somatic cells can be challenging, and repro-
gramming efficiency may be compromised by their severe 
pathophysiological defects. As examples, the generation 
of iPSC colonies for Gaucher disease, Pearson syndrome, 
Mucopolysaccharidosis type IIIB (MPSIIIB), Pompe dis-
ease, or NPC was found to be reduced when compared 
with that of healthy somatic cells [29, 49–53]. In a study 
by Huang et al. reprogramming fibroblasts from Pompe 
disease patients was not possible unless they conditionally 
rescued the expression of alpha-glucosidase (GAA) [51]. 
Nevertheless, later studies [54–57] successfully generated 
iPSC from infantile-onset and late-onset Pompe disease 
patients without the need of using rescue-based strate-
gies. Similarly, iPSC generation from MPSIIIB patients 
by Lemonnier et al. required the exogenous complemen-
tation of the enzymatic defect [52]. In this case, repro-
gramming of MPSIIIB cells was efficient, but patient iPSC 
Fig. 2  Main cell types differen-
tiated from hiPSC for modeling 
of IEMs. Pie chart indicating 
the main cell types differenti-
ated from hiPSC and used for 
disease modeling of IEMs in the 
reviewed literature, displayed 
following alphabetical order in 
clockwise direction. Out of the 
20 different cell types identified 
in the relevant literature, neural 
derivatives and cardiomyocytes 
were used in over 50% of the 
published studies
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proliferated poorly and were inefficiently cloned unless the 
missing enzyme (α-N-acetyl-glucosaminidase) was exog-
enously supplied [52]. Lastly, iPSC generation was also 
hampered in NPC [29]. The authors initially found that 
only a few iPSC-like colonies appeared during the repro-
gramming process, disappearing after 5–7 passages. The 
difficulty in NPC-iPSC generation was due to cholesterol 
accumulation in fibroblasts. Thus, after the treatment of 
NPC fibroblasts with tocopherol, a compound that reduces 
cholesterol accumulation, NPC-iPSC stable in culture for 
over 20 passages could be successfully established [29].
IEMs encompass a plethora of highly diverse disorders. 
The presence and severity of the disease can also vary within 
individuals carrying the same pathogenic mutation. In any 
case, the known IEM mutations observed in patients are 
not developmentally lethal, and the early stages during the 
embryonic development are not severely compromised. In 
this regard, although the reprogramming efficiency might 
occasionally be reduced, the metabolic defects underlying 
IEMs do not seem to affect the generation and maintenance 
of iPSCs, which has been accomplished for dozens of these 
disorders. This finding reinforces iPSC technology as an 
important experimental tool to provide valuable insights 
into the pathophysiology of these diseases, further encour-
aging researchers to apply this powerful approach for IEM 
modeling.
3.3  Third lesson: Variability needs to be accounted 
for when using iPSC to model IEMs
A defining characteristic of pluripotent stem cells is their 
potential to differentiate into cells of all three germ layers. 
However, a limiting factor regarding the use of iPSCs is, 
precisely, the variability in their differentiation potential. 
Not only the inter-individual differences among iPSC may 
have a strong impact in the differentiation capacity toward 
a specific cell type, but also between hiPSC clones from the 
same individual [58, 59]. There have been several attempts 
to characterize the sources of such variability. Prolonged 
culture and maintenance of pluripotent stem cells has been 
shown to promote genomic alterations, most frequently 
on chromosomes 12 and 17, likely reflecting the selective 
pressure processes taking place in culture [60]. Frequent 
amplifications of the WNT3/WNT9B cluster in the 17q21 
chromosomal region have also been found to have impor-
tant functional consequences affecting neural differentiation 
[61]. More recently, a comprehensive examination of the 
major sources of genetic and phenotypic variations in iPSC 
lines was undertaken by genome-wide characterization of 
711 iPSC lines derived from 301 healthy individuals, estab-
lished by the Human Induced Pluripotent Stem Cells Initia-
tive (HipSci). The authors were able to identify consistent 
inter-individual effects that explained more than 46% of the 
phenotypic variation among iPSC lines [62].
Irrespective of the origin, phenotypic interline variabil-
ity of iPSCs complicates assigning specific genotypes to 
disease-related cellular phenotypes. In this sense, the use 
of targeted nucleases as gene-editing tools is increasingly 
being used to counteract such variability, enabling the gen-
eration of isogenic controls that only differ in the presence/
absence of the genetic variants under study. The versatility 
of targeting almost any locus in the genome to generate the 
desired targeted genetic modification becomes essential for 
the interpretation of the results and to strengthen the rela-
tionship between the genotype and phenotype.
The earliest attempts at generating sequence-specific 
changes in IEMs-derived iPSC were established with 
BAC- or AAV-based vectors targeting the ornithine-δ-
aminotransferase (OAT) and HPRT1 gene [63, 64]. Engi-
neered nucleases, such as TALENs and zinc-finger nucleases 
(ZFN) have also been used to introduce specific mutations 
in iPSCs to model several diseases, such as ubiquinone 
deficiency, pyruvate kinase deficiency, NPC or LDLR defi-
ciency [65–68]. More recently, CRISPR/Cas9 has emerged 
as the leading genome-editing technique in the context of 
iPSC-based disease modeling. The advent of CRISPR/Cas9 
technology has opened unprecedented opportunities for this 
purpose due to its simplicity [69]. Successful efforts have 
been made in modeling inherited hypercholesterolemia with 
iPSC-corrected isogenic controls. Omer et al. and Okada 
et al. used CRISPR/Cas9 to correct a 3-base pair homozy-
gous deletion and a homozygous point mutation in the 
LDLR gene, respectively, restoring low-density lipoprotein- 
cholesterol (LDL-C) uptake [70–72]. Recent studies gener-
ated corrected-isogenic controls of Fabry- iPSC lines carry-
ing heterozygous mutations in the GLA gene. Differentiated 
cardiomyocytes and vascular endothelial cells from gene-
corrected iPSC lines displayed restored levels of α-gal A 
protein [73, 74]. CRISPR/Cas9-based modeling of Sand-
hoff disease has also been achieved using isogenic controls 
in which one of the mutant alleles in the HEXB gene was 
corrected. In this way, cerebral organoids from mutant and 
gene-corrected iPSC were developed, demonstrating that 
accumulation of GM2 ganglioside was diminished and the 
neuronal differentiation was not impaired in isogenic con-
trols when compared with the mutant HEXB line [75].
The use of genetic engineering and iPSC technology is 
a powerful combination especially for ultra-rare diseases 
where patients’ samples for iPSC generation are particularly 
limited. In order to overcome this limitation, specific muta-
tions can be introduced in healthy control iPSC. Although 
the complex genomic background of real patients is not 
recapitulated when using control iPSC, these efforts pro-
vide valuable insights into the pathogenesis of specific gene 
mutations [76, 77].
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The generation of iPSCs from healthy and diseased indi-
viduals allows capturing the complex genomic background 
from each individual. Genomic variability may impact in the 
differentiation capacity towards the cell of interest or even 
in the observed phenotypes. Thus, formally ascribing the 
appearance of disease-related phenotypes to the presence 
of particular gene mutations often requires the analysis of 
isogenic control cells that only differ in the specific mutation 
of interest. Although the studies combining iPSCs and gene-
editing techniques for the modeling of IEMs are still only a 
small fraction (Fig. 1B), there is an increasing trend towards 
the use of such techniques in recent years, highlighting the 
importance of genome edition to address causality between 
gene mutations/variants and disease phenotypes.
3.4  Fourth lesson: High‑content/throughput 
screens may be feasible, but still a long way 
to go
For decades, the identification of novel compounds for 
treating human conditions has relied on high-throughput 
screening systems primarily based on cellular assays. Most 
cell-based screening assays have used either immortalized 
tumor-derived cell lines, in which the desired molecular 
target is heterologously expressed, or primary cells that 
better resemble the functions and phenotypes found in vivo 
[78]. Although more physiologically and preclinically rel-
evant than immortalized cells, disadvantages of primary 
cell cultures such as their limited expansion and thus avail-
ability, have precluded their widespread adoption in high-
throughput screening of small compounds. Major efforts 
are now aimed toward the use of iPSCs in drug discovery 
as they provide theoretically unlimited, homogeneous cell 
populations for cell type-specific compound screening, pro-
filing and optimization [40, 79].
Although iPSC technology has facilitated the understand-
ing of disease pathogenesis and the impact of compound 
modulators, drug development for monogenic diseases, 
including those related to IEMs, is still challenging [34, 80, 
81]. In the field of lysosomal storage disorders much atten-
tion has been directed to target-based drug testing. Lyso-
somal accumulation of sphingolipids or cholesterol esters 
has been observed in iPSC-based models of Tay-Sachs, 
Niemann-Pick disease type A, B and C, Neural Ceroid Lipo-
fuscinoses, and Wolman disease. In these studies, treatment 
with tocopherols and hydroxypropyl-cyclodextrins amelio-
rate lysosomal cholesterol and lipid accumulation, indicating 
their potential therapeutic use for these diseases [29, 67, 
82–86]. Gaucher disease is arguably the most characterized 
iPSC model of lysosomal disorders, probably owing to the 
fact that mutations in the glucocerebrosidase gene (GBA1) 
constitute an important genetic risk factor for Parkinson’s 
disease (PD) [87]. In recent years, several target-based 
compound screens have been performed to identify mol-
ecules capable of decreasing the accumulation of gluco-
sylsphingosine. In a study by Kim et al. inhibition of acid 
ceramidase by carmofur resulted, not only in the reduction 
of glucosylsphingosine levels, but also in a decrease in 
oxidized α-synuclein levels in GBA1-PD patient-derived 
dopaminergic neurons [88]. More recently, a small molecule 
inhibitor of mTOR (Torin 1) was able to upregulate lysoso-
mal biogenesis and to enhance the autophagic clearance of 
Gaucher neurons [89].
However, the use of iPSC-based models of IEMs for 
medium- and high-throughput screening approaches is 
scarce to date. This most likely reflects the inherent chal-
lenges in generating disease affected cell types at high 
scale and purity [40]. In a study from Cayo et al. iPSC-
derived hepatocytes from familial hypercholesterolemia 
patients were used to perform a large screening of existing 
drugs that could potentially increase exogenous LDL traf-
ficking to endosomes and reduce exogenous LDL-C levels, 
including apoB. A total of 2,320 existing small molecules 
were tested for their ability to reduce apoB levels. The 
authors found that cardiac glycosides, such as digoxin, 
proscillaridin or ouabain, could lower the levels of apoB in 
culture medium by promoting its proteolytic turnover [90]. 
In a second high-content drug screening, the same labora-
tory generated a deoxyguanosine kinase (DGUOK) loss-
of-function iPSC using CRISPR/Cas9 and differentiated 
them into hepatocyte-like cells [91]. DGUOK deficiency 
is the most common cause of mitochondrial DNA deple-
tion syndrome, in which the production of deoxyadenosine 
monophosphate (dAMP) and deoxyguanosine monophos-
phate (dGMP) is diminished mainly in the liver. Using 
the same drug collection library, the authors interrogated 
the compounds for their ability to restore ATP levels in 
DGUOK-deficient hepatocytes. They identified  NAD+ as 
a potential drug candidate that could increase not only 
ATP levels, but also the expression of all mitochondrial-
encoded electron transport chain genes examined in vitro 
and in vivo [91]. Recently, iPSC-derived neurons have 
been used in two high-content drug screenings. In one 
study, neuronal progenitor cells from GM1 gangliosidosis 
were tested with 2.217 already approved drugs. Two com-
pounds, amodiaquine and thiethylperazine were capable 
of activating autophagy both in vitro and in vivo [92]. In a 
second study, Lesch-Nyhan-derived neural progenitor cells 
were screened with 3.838 pharmacological compounds for 
their ability to increase cell viability. The authors iden-
tified 6 adenosine-like compounds that ameliorated cell 
survival and neurogenesis in HGPRT-deficient cells [93].
Over the past few years, compound-screening assays 
using iPSC-derived cells has emerged as a new powerful 
strategy for the pharmaceutical industry, facilitating target 
and lead identification, and lead optimization. However, 
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there is still a long way to go in the context of IEMs. iPSCs 
are particularly important given that they can be reproduc-
ibly cultured in high abundance and give rise to different 
cell types from the same individual, which facilitates opti-
mization for compound safety, selectivity and efficacy. In 
addition, the importance of stringent quality controls and 
well defined and established workflows at every stage of the 
process will be indispensable for the identification of novel 
compounds, and thus for the successful use of iPSC-based 
platforms for drug discovery and preclinical studies.
3.5  Fifth lesson: iPSC‑based technology opens 
the door to modeling pre‑clinical stages 
of disease
Theoretically at least, almost any genetic disease lends 
itself to be modeled employing iPSC-based technology. 
However, this strategy has proved so far to be more ame-
nable for tackling monogenic diseases associated to highly 
penetrant disease-causing mutations, as opposed to environ-
mentally modulated, sporadic or diseases of unknown cause 
[94]. Congenital or early-onset diseases also appear to be 
more readily modeled in vitro using iPSC-based strategies 
than late-onset diseases. This could be linked to the fact 
that current iPSC differentiation protocols yield cells with 
immature or fetal-like characteristics, but it may reflect the 
difficulty of recapitulating aging, a major risk factor in many 
late-onset diseases, in standard laboratory conditions. These 
limitations notwithstanding, several studies have decribed 
the appearance of disease-related phenotypes in iPSC-based 
models of PD, Huntington disease, and Alzheimer’s disease 
[95, 96]. Although these disorders may appear late in life, 
aberrant molecular and cellular phenotypes are detectable 
in culture, illustrating the possibility to study early stages of 
disease progression.
Canals et  al. generated an iPSC-based experimental 
model of Sanfilippo type C syndrome, a lysosomal storage 
disorder with progressive neurodegeneration [97]. Differ-
entiated mature neurons were able to recapitulate the main 
known phenotypes of the disease, such as the accumula-
tion of glycosaminoglycan (GAG) over time and abnormal 
vacuoles morphology. The authors found that neuronal GAG 
accumulation was not statistically significant until cells had 
been in culture for 9 weeks, in concordance with the pro-
gressive nature of the disease. However, the authors found 
that neuronal network activity and connectivity were already 
altered at 3 weeks of differentiation, suggesting that similar 
approaches could be used to detect early functional signs 
that predate the clinical onset of other diseases as well. If 
realized, this would facilitate the identification of potential 
therapeutic strategies that would prevent, rather than revert, 
the appearance of clinical signs of the disease in patients.
3.6  Sixth lesson: Advanced culture systems, new 
tools to overcome the limitations of 2D cultures
One of the main challenges associated with iPSC-based exper-
imental approaches is the relative immaturity of iPSC deriva-
tives obtained with current differentiation protocols, which 
are typically carried out under standard two dimensional (2D) 
culture conditions [98, 99]. It is commonly thought that 2D 
cell culture systems lack critical information cues for cell dif-
ferentiation/maturation, including tissue-specific architecture 
and biomechanical and biochemical signals originating from 
cell–cell and cell–matrix interactions [100]. Many of those 
information cues are present in organoid-type 3D culture sys-
tems, which offer levels of cell differentiation, tissue organiza-
tion and response to drugs more closely resembling the in vivo 
situation [101, 102].
For example, Akbari et al. reported on the generation of 
functional hepatic organoids for Citrullinemia type I that reca-
pitulated important disease-related phenotypes such as the 
decrease in ammonia detoxification capacity [103]. Similarly, 
a robust spinal cord organoid system derived from iPSCs of a 
MELAS (Mitochondrial encephalomyopathy, lactic acidosis 
and stroke episodes) patient was developed to further investi-
gate the neurogenesis defects in this disease. Motor neurons, 
which could not be reproducibly obtained using conventional 
2D differentiation protocols, were reproducibly generated in 
the organoid model [104]. More recently, a brain organoid 
model of Leigh syndrome, the most severe pediatric manifes-
tation of mitochondrial diseases, revealed compromised neural 
morphogenesis due to defective metabolic state. This model 
offers hope for solving a major obstacle for developing effec-
tive therapies for this syndrome: the lack of suitable model 
systems recapitulating the human disease course. Thanks to 
this model, Inak et al. provided novel mechanistic insights and 
suggested potential interventional strategies for this incurable 
disease [105].
Organoids are valuable tools for precision medicine and, in 
combination with genetic-engineering approaches, can be used 
to directly test the role of pathogenic mutations in a controlled 
environment. Despite the numerous advantages of organoids 
over conventional 2D cell culture systems, some limitations 
remain, such as the relative lack of standardized protocols to 
generate organoids and the absence of vascularization and 
of complex inter-organ communication. To address current 
technical challenges in organoid research, the integration of 
organoids with microfluidic on-a-chip devices is emerging as 
an advanced, yet complementary, bioengineering approach. 
Organ-on-a-chip devices are able to control the biochemical 
and biophysical microenvironment, resulting in increased 
tissue maturation and vascularization, and offering a more 
in vivo-like phenotype with multi-organ capabilities for IEM 
disease modelling [106–108]. A pioneering adoption of on-a-
chip approaches in the field of IEM modeling investigated the 
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pediatric cardiomyopathy Barth syndrome. Combining gene 
editing and heart-on-a-chip technology, the authors were able 
to provide new insights into the disease mechanisms [108]. 
However, organ-on-a-chip devices are typically of very low 
throughput, limiting its applicability in the early stages of drug 
discovery [109].
4  Concluding remarks
The ability to reprogram somatic cells to iPSCs is gradu-
ally changing the way we develop experimental disease 
models, especially for rare monogenic diseases, offsetting 
the limited number of patients available worldwide, the 
difficulty in gaining access to the mostly affected tissues, 
and the lack of bona fide experimental animal models. 
The combination of human iPSC-based technology and 
site-directed genome edition constitutes an exciting and 
powerful platform for complex disease modeling and drug 
screening. However, despite the promising advantages 
offered by combining these two technologies, important 
limitations and challenges need to be taken into account if 
disease models are to be exploited to their fullest (Fig. 3). 
Efforts at modeling human diseases in general, and IEMs 
in particular, have taught us already some lessons that we 
believe ought to be considered when devising future exper-
imental models (Fig. 4): 1) iPSC technology emphasizes 
the importance of the disease-relevant cell types. Fibro-
blasts can provide valuable readouts for primary screen-
ing of novel compounds, but the differential response 
between fibroblasts and the specific cell type(s) affected 
in the disease highlights that, in many cases, iPSC-based 
cell models could be the preferred option for this purpose; 
2) the characteristic metabolic defects that underlie IEMs 
do not seem to affect iPSC generation and maintenance, 
reinforcing iPSC technology as an important experimental 
tool to provide insights into the pathophysiology of IEMs; 
3) the inter-line and inter-clone variability in differentia-
tion potential of iPSCs needs to be accounted for when 
modeling IEM. A straightforward manner to address this 
limitation consists on the parallel interrogation of isogenic 
controls, which are currently easily generated thanks to 
CRISPR/Cas9-based genomic edition technology; 4) 
although still a long way to go in the context of IEMs, 
iPSCs-based models emerge as serious candidates to be 
used as medium- and high-throughput screening platforms 
since they can provide theoretically unlimited amounts 
of homogeneous, patient-specific, and disease-relevant 
cell types; 5) iPSC-based technology offers the possibil-
ity to model pre-clinical stages of late-onset diseases and 
to identify early functional signs that predate the clinical 
phenotypes. This pre-clinical time window could facili-
tate the development of potential therapeutic strategies 
that would prevent the appearance of clinical disease; and 
6) Advanced culture systems hold remarkable potential 
for increasing the maturation state of iPSC derivatives, 
thus extending the validity of such disease models to phe-
notypes not easily attainable in conventional 2D culture 
systems.
In conclusion, carefully designed and properly controlled 
iPSC-based models of IEMs recapitulate key features of the 
disease phenotype and respond to pharmacologic manipu-
lation predictably. As such, iPSC-based models of IEMs 
have enabled uncovering the role of novel pathogenic 
mechanisms in sialidosis and NPC, identifying new drug 
compounds potentially effective for DGUOK deficiency 
Fig. 3  Comparison of different cell culture systems for modeling of 
IEMs. Patient-specific fibroblasts, along with their reprogrammed 
hiPSC and hiPSC-derivatives (in form of 2D cell cultures or orga-
noid systems), are compared for their relative limitations and benefits. 
Score marks are represented as follows: ‘ + ’: not suitable; ‘ + + ’: 
good and ‘ + + + ’: optimal
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and hypercholesterolemia, and developing novel drug can-
didates and target pathways for GM1 gangliosidosis, among 
many other examples of success. Whereas remarkable pro-
gress has been made over the past decade, iPSC technology 
is still in its infancy and important challenges will need to 
be addressed. Of note, the functional immaturity of iPSC-
derived cells is an important consideration when studying 
IEM and age-related diseases. As developments in iPSC 
technology itself progress towards better reproducibility 
and scalability, we believe that iPSC-based approaches will 
become a powerful tool for precision medicine, capable of 
predicting disease trajectories and potential effective treat-
ments at the individual level, not only for IEMs but also 
applicable to many other diseases.
Fig. 4  Schematic representation of the lessons learnt from iPSC mod-
els of IEMs. Somatic cells such as fibroblasts can be obtained from 
patients with IEMs to study pathogenic mechanisms, but in a cellu-
lar and metabolic context that may differ from that of disease-affected 
cells. Somatic cells can be reprogrammed into iPSC carrying the 
IEM-specific genetic alteration. iPSC can be differentiated into the 
disease-relevant cell type (such as cardiomyocytes to study disorders 
of energy metabolism or glycogen storage disorders). CRISPR/Cas9-
based gene-editing technology allows the generation of isogenic sets 
of iPSC that can be used to properly associate genetic alterations to 
specific phenotypes. The combination of gene editing and iPSC tech-
nology is a remarkable tool to study preclinical stages (such as the 
neural defects in Sanfilippo C) and to perform high-throughput drug 
screenings (for example to reduce the hypercholesterolemia in iPSC-
derived hepatocytes). The immature phenotype of iPSC derivatives 
is a current limitation in the field, which can be overcome by using 
advanced culture systems such as organoids and organ-on-a-chip 
devices, which generate cells more similar to their in vivo counter-
part, making them suitable for high-content screenings and lead opti-
mization
 Reviews in Endocrine and Metabolic Disorders
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